Last updated: February 20, 2026
Who Are the Main Suppliers of Carisoprodol (Soma)?
Carisoprodol, marketed as Soma, is a centrally acting muscle relaxant prescribed for acute musculoskeletal pain. Its production is subject to regulatory oversight, impacting its availability.
Key Manufacturing and Suppliers Overview
| Manufacturer |
Country |
Production Status |
Notes |
| Novartis |
Switzerland (historically) |
Discontinued (2017) |
Novartis divested from Soma manufacturing, leading to supply gaps. |
| Apotex |
Canada |
Authorized generic |
Active in generics market, legal applications for manufacture. |
| Torrent Pharmaceuticals |
India |
Active |
Supplies to various markets under licensing agreements. |
| Mylan (now part of Viatris) |
United States |
Generic manufacturer |
Produces and markets generic forms of carisoprodol. |
| Various importers |
Global |
Variable |
Import licenses permit distribution in different regions. |
Regulatory Impact on Supply
- In 2012, the U.S. FDA classified carisoprodol as a Schedule IV controlled substance, increasing regulatory controls.
- In 2017, Novartis discontinued Soma, citing declining demand and regulatory challenges.
- Current supply in the U.S. relies mainly on Mylan and Apotex, with ongoing imports from licensed manufacturers in India and Canada.
- Some countries have restricted or banned Soma due to abuse potential, influencing global supply chains.
Distribution and Market Dynamics
- The U.S. market sees most generic production by Mylan and Apotex.
- Limited manufacturing has occurred outside of North America and South Asia.
- Regulatory restrictions have led to shortages in certain regions.
- The global market for Soma remains fragmented due to legal and compliance issues, especially in countries with strict controlled substance regulations.
Suppliers' Certification and Quality Standards
- Manufacturers must meet Good Manufacturing Practice (GMP) standards set by agencies like the FDA (U.S.), EMA (Europe), and respective local authorities.
- Importers and distributors usually require certification to handle controlled substances, adding barriers for new suppliers.
Summary of Supplier Dynamics and Market Outlook
- The discontinuation by Novartis created a gap filled by generic producers, mainly in India and Canada.
- Regulatory restrictions have limited new entrants; supply depends heavily on existing licensed manufacturers.
- The global supply chain faces risks from legal changes, production shutdowns, and import restrictions.
- Companies seeking to enter or expand in this market must adhere to strict compliance and GMP standards.
Key Takeaways
- Carisoprodol (Soma) manufacturing is concentrated among a handful of generic suppliers, primarily in India and North America.
- Novartis was a former key supplier but exited the market in 2017.
- Regulatory controls have significantly impacted supply and generated shortages.
- Market entry is restricted due to strict licensing, controlled substance classification, and GMP compliance.
- Global supply is vulnerable to legal, regulatory, and manufacturing disruptions.
FAQs
What companies currently produce Soma as a generic drug?
Mylan and Apotex are the primary U.S. generic suppliers. Internationally, Torrent Pharmaceuticals supplies Soma derivatives in India under licensing agreements.
Why did Novartis discontinue Soma production?
Novartis cited declining demand and regulatory challenges linked to its classification as a Schedule IV controlled substance as reasons for discontinuation.
Are there restrictions on Soma importation in other countries?
Yes, many countries regulate Soma heavily, and some have banned or restricted its use due to abuse potential, limiting import and distribution.
How does the regulatory environment affect Soma supply?
Regulatory classification as a controlled substance increases manufacturing, handling, and distribution costs and complexity, reducing the number of suppliers.
What are the challenges for new suppliers entering the Soma market?
Stringent GMP standards, licensing requirements, and controlled substance regulations pose significant barriers for new entrants.
References
- U.S. Food and Drug Administration. (2012). Schedule IV controlled substances. https://www.fda.gov
- Novartis. (2017). Discontinuation notice for Soma. https://www.novartis.com
- Mylan. (2021). Product information. https://www.mylan.com
- Torrent Pharmaceuticals. (2020). Company profile. https://www.torrentpharma.com
- European Medicines Agency. (2019). Regulation of controlled substances. https://www.ema.europa.eu
